Mitochondrial Reprogramming induced by CaMKIIδmediates hypertrophy decompensation

Circulation Research

Volumn 116, Issue 5, 2015, Pages e28-e39

  Daan Westenbrink, B ^a,e   Ling, Haiyun ^a   Divakaruni, Ajit S ^a   Gray, Charles B B ^a,c   Zambon, Alexander C ^a   Dalton, Nancy D ^b   Peterson, Kirk L ^b   Gu, Yusu ^b   Matkovich, Scot J ^d   Murphy, Anne N ^a   Miyamoto, Shigeki ^f   Dorn, Gerald W ^c   Brown, Joan Heller ^a  

^a San Diego   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f NONE

Author keywords

Calcium calmodulin dependent protein kinase type 2; G protein; Gq; Heart failure; Mitochondrial uncoupling protein 3; Oxidative stress

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA; GALPHAQ TRANSGENIC PROTEIN; PEPTIDES AND PROTEINS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 3; ACETYLCYSTEINE; BENZYLAMINE DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; ION CHANNEL; MESSENGER RNA; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN 3; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; SMALL INTERFERING RNA; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREATHING RATE; CONTROLLED STUDY; GENE DELETION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; ANIMAL; BIOSYNTHESIS; CARDIAC MUSCLE CELL; CARDIOMEGALY; CARDIOMYOPATHY, DILATED; CELL CULTURE; DEFICIENCY; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; HEART MITOCHONDRION; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; POINT MUTATION; PRESSURE; RAT; RNA INTERFERENCE; SEQUENCE ANALYSIS; TRANSGENIC MOUSE;

ACETYLCYSTEINE; ANIMALS; APOPTOSIS; BENZYLAMINES; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CARDIOMEGALY; CARDIOMYOPATHY, DILATED; CELLS, CULTURED; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEART FAILURE; ION CHANNELS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MITOCHONDRIA, HEART; MITOCHONDRIAL PROTEINS; MYOCYTES, CARDIAC; OXIDATIVE STRESS; POINT MUTATION; PPAR ALPHA; PRESSURE; RATS; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, RNA; SULFONAMIDES; TRANSFECTION;

EID: 84924548852     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.304682     Document Type: Article

References (47)

1. Dorn GW II. The fuzzy logic of physiological cardiac hypertrophy. Hypertension. 2007;49:962-970. doi: 10.1161/HYPERTENSIONAHA.106.079426.
2. Kannel WB, Doyle JT, McNamara PM, Quickenton P, Gordon T. Precursors of sudden coronary death. Factors related to the incidence of sudden death. Circulation. 1975;51:606-613.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566. doi: 10.1056/NEJM199005313222203.
4. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol. 2003;65:45-79. doi: 10.1146/annurev.physiol.65.092101.142243.
5. D'Angelo DD, Sakata Y, Lorenz JN, Boivin GP, Walsh RA, Liggett SB, Dorn GW II. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A. 1997;94:8121-8126.
6. Wettschureck N, Rütten H, Zywietz A, Gehring D, Wilkie TM, Chen J, Chien KR, Offermanns S. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med. 2001;7:1236-1240. doi: 10.1038/nm1101-1236.
7. Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51:468-473. doi: 10.1016/j.yjmcc.2011.01.012.
8. Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J Jr, Bers DM, Brown JH. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res. 2003;92:912-919. doi: 10.1161/01.RES.0000069686.31472.C5.
9. Ling H, Zhang T, Pereira L, Means CK, Cheng H, Gu Y, Dalton ND, Peterson KL, Chen J, Bers D, Brown JH, Heller Brown J. Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest. 2009;119:1230-1240. doi: 10.1172/JCI38022.
10. Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM, Grueter CE, Qi X, Richardson JA, Hill JA, Katus HA, Bassel-Duby R, Maier LS, Olson EN. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A. 2009;106:2342-2347. doi: 10.1073/pnas.0813013106.
11. Zhang R, Khoo MS, Wu Y, et al. Calmodulin kinase II inhibition protects against structural heart disease. Nat Med. 2005;11:409-417. doi: 10.1038/nm1215.
12. Ling H, Gray CB, Zambon AC, Grimm M, Gu Y, Dalton N, Purcell NH, Peterson K, Brown JH. Ca2+/Calmodulin-dependent protein kinase II δ mediates myocardial ischemia/reperfusion injury through nuclear factor-κB. Circ Res. 2013;112:935-944. doi: 10.1161/CIRCRESAHA.112.276915.
13. Zhang T, Guo T, Mishra S, Dalton ND, Kranias EG, Peterson KL, Bers DM, Brown JH. Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice. Circ Res. 2010;106:354-362. doi: 10.1161/CIRCRESAHA.109.207423.
14. Lancel S, Qin F, Lennon SL, Zhang J, Tong X, Mazzini MJ, Kang YJ, Siwik DA, Cohen RA, Colucci WS. Oxidative posttranslational modifications mediate decreased SERCA activity and myocyte dysfunction in Galphaq-overexpressing mice. Circ Res. 2010;107:228-232. doi: 10.1161/CIRCRESAHA.110.217570.
15. Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintrón M, Chen T, Marcinek DJ, Dorn GW II, Kang YJ, Prolla TA, Santana LF, Rabinovitch PS. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res. 2011;108:837-846. doi: 10.1161/CIRCRESAHA.110.232306.
16. Satoh M, Matter CM, Ogita H, Takeshita K, Wang CY, Dorn GW II, Liao JK. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation. 2007;115:3197-3204. doi: 10.1161/CIRCULATIONAHA.106.657981.
17. Elrod JW, Wong R, Mishra S, Vagnozzi RJ, Sakthievel B, Goonasekera SA, Karch J, Gabel S, Farber J, Force T, Brown JH, Murphy E, Molkentin JD. Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest. 2010;120:3680-3687. doi: 10.1172/JCI43171.
18. Joiner ML, Koval OM, Li J, et al. CaMKII determines mitochondrial stress responses in heart. Nature. 2012;491:269-273. doi: 10.1038/nature11444.
19. Matkovich SJ, Zhang Y, Van Booven DJ, Dorn GW II. Deep mRNA sequencing for in vivo functional analysis of cardiac transcriptional regulators: application to Galphaq. Circ Res. 2010;106:1459-1467. doi: 10.1161/CIRCRESAHA.110.217513.
20. Rogers GW, Brand MD, Petrosyan S, Ashok D, Elorza AA, Ferrick DA, Murphy AN. High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria. PLoS One. 2011;6:e21746.
21. Miyamoto S, Purcell NH, Smith JM, Gao T, Whittaker R, Huang K, Castillo R, Glembotski CC, Sussman MA, Newton AC, Brown JH. PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res. 2010;107:476-484. doi: 10.1161/CIRCRESAHA.109.215020.
22. Chen R, Liang F, Morimoto S, Li Q, Moriya J, Yamakawa J, Takahashi T, Iwai K, Kanda T. The effects of a PPARalpha agonist on myocardial damage in obese diabetic mice with heart failure. Int Heart J. 2010;51:199-206.
23. Azzu V, Jastroch M, Divakaruni AS, Brand MD. The regulation and turnover of mitochondrial uncoupling proteins. Biochim Biophys Acta. 2010;1797:785-791. doi: 10.1016/j.bbabio.2010.02.035.
24. Yang S, Chen C, Wang H, Rao X, Wang F, Duan Q, Chen F, Long G, Gong W, Zou MH, Wang DW. Protective effects of Acyl-coA thioesterase 1 on diabetic heart via PPARα/PGC1α signaling. PLoS One. 2012;7:e50376. doi: 10.1371/journal.pone.0050376.
25. Dubchak I, Munoz M, Poliakov A, Salomonis N, Minovitsky S, Bodmer R, Zambon AC. Whole-Genome rVISTA: a tool to determine enrichment of transcription factor binding sites in gene promoters from transcriptomic data. Bioinformatics. 2013;29:2059-2061. doi: 10.1093/bioinformatics/btt318.
26. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation. 2002;105:85-92.
27. Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu PP, Cleland JG, Maggioni A, Fonarow GC, Abel ED, Campia U, Gheorghiade M. Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur J Heart Fail. 2012;14:120-129. doi: 10.1093/eurjhf/hfr173.
28. Treuting PM, Linford NJ, Knoblaugh SE, Emond MJ, Morton JF, Martin GM, Rabinovitch PS, Ladiges WC. Reduction of age-associated pathology in old mice by overexpression of catalase in mitochondria. J Gerontol A Biol Sci Med Sci. 2008;63:813-822.
29. Dai DF, Santana LF, Vermulst M, Tomazela DM, Emond MJ, MacCoss MJ, Gollahon K, Martin GM, Loeb LA, Ladiges WC, Rabinovitch PS. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation. 2009;119:2789-2797. doi: 10.1161/CIRCULATIONAHA.108.822403.
30. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, Oyabu J, Murakawa T, Nakayama H, Nishida K, Akira S, Yamamoto A, Komuro I, Otsu K. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature. 2012;485:251-255. doi: 10.1038/nature10992.
31. Erickson JR, Joiner ML, Guan X, et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell. 2008;133:462-474. doi: 10.1016/j.cell.2008.02.048.
32. Swaminathan PD, Purohit A, Soni S, et al. Oxidized CaMKII causes cardiac sinus node dysfunction in mice. J Clin Invest. 2011;121:3277-3288. doi: 10.1172/JCI57833.
33. He BJ, Joiner ML, Singh MV, et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med. 2011;17:1610-1618. doi: 10.1038/nm.2506.
34. Erickson JR, He BJ, Grumbach IM, Anderson ME. CaMKII in the cardiovascular system: sensing redox states. Physiol Rev. 2011;91:889-915. doi: 10.1152/physrev.00018.2010.
35. Mailloux RJ, Seifert EL, Bouillaud F, Aguer C, Collins S, Harper ME. Glutathionylation acts as a control switch for uncoupling proteins UCP2 and UCP3. J Biol Chem. 2011;286:21865-21875. doi: 10.1074/jbc.M111.240242.
36. Divakaruni AS, Brand MD. The regulation and physiology of mitochondrial proton leak. Physiology (Bethesda). 2011;26:192-205. doi: 10.1152/physiol.00046.2010.
37. Bugger H, Guzman C, Zechner C, Palmeri M, Russell KS, Russell RR III. Uncoupling protein downregulation in doxorubicin-induced heart failure improves mitochondrial coupling but increases reactive oxygen species generation. Cancer Chemother Pharmacol. 2011;67:1381-1388. doi: 10.1007/s00280-010-1441-7.
38. Mailloux RJ, Dumouchel T, Aguer C, deKemp R, Beanlands R, Harper ME. Hexokinase II acts through UCP3 to suppress mitochondrial reactive oxygen species production and maintain aerobic respiration. Biochem J. 2011;437:301-311. doi: 10.1042/BJ20110571.
39. Liu D, Huang L, Wang Y, Wang W, Wehrens XH, Belousova T, Abdelrahim M, DiMattia G, Sheikh-Hamad D. Human stanniocalcin-1 suppresses angiotensin II-induced superoxide generation in cardiomyocytes through UCP3-mediated anti-oxidant pathway. PLoS One. 2012;7:e36994. doi: 10.1371/journal.pone.0036994.
40. Boudina S, Han YH, Pei S, Tidwell TJ, Henrie B, Tuinei J, Olsen C, Sena S, Abel ED. UCP3 regulates cardiac efficiency and mitochondrial coupling in high fat-fed mice but not in leptin-deficient mice. Diabetes. 2012;61:3260-3269. doi: 10.2337/db12-0063.
41. Ozcan C, Palmeri M, Horvath TL, Russell KS, Russell RR III. Role of uncoupling protein 3 in ischemia-reperfusion injury, arrhythmias, and preconditioning. Am J Physiol Heart Circ Physiol. 2013;304:H1192-H1200. doi: 10.1152/ajpheart.00592.2012.
42. Perrino C, Schiattarella GG, Sannino A, et al. Genetic deletion of uncoupling protein 3 exaggerates apoptotic cell death in the ischemic heart leading to heart failure. J Am Heart Assoc. 2013;2:e000086. doi: 10.1161/JAHA.113.000086.
43. Sarma S, Ardehali H, Gheorghiade M. Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure. Heart Fail Rev. 2012;17:35-43. doi: 10.1007/s10741-010-9208-0.
44. Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, Yamada A, Kato T, Izawa H, Murohara T, Yokota M. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors. J Mol Cell Cardiol. 2006;41:318-329. doi: 10.1016/j.yjmcc.2006.05.013.
45. Swaminathan PD, Purohit A, Hund TJ, Anderson ME. Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. Circ Res. 2012;110:1661-1677. doi: 10.1161/CIRCRESAHA.111.243956.
46. Grimm M, Ling H, Brown JH. Crossing signals: relationships between β-adrenergic stimulation and CaMKII activation. Heart Rhythm. 2011;8:1296-1298. doi: 10.1016/j.hrthm.2011.02.027.
47. Nishio S, Teshima Y, Takahashi N, Thuc LC, Saito S, Fukui A, Kume O, Fukunaga N, Hara M, Nakagawa M, Saikawa T. Activation of CaMKII as a key regulator of reactive oxygen species production in diabetic rat heart. J Mol Cell Cardiol. 2012;52:1103-1111. doi: 10.1016/j.yjmcc.2012.02.006.